ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 332

Serum 25-Hydroxyvitamin D, Acute Phase Reactants and Disease Activity in Rheumatologic Diseases

María Lorena Brance1,2, Lucas Ricardo Brun3, Maria Larroude4, Mónica Patricia Sacnun5, Carolina Aeschlimann5, Guillermo Berbotto6, Mariano Palatnik1, Ignacio Chavero1 and Ariel Sánchez7, 1Centro de Reumatología, Rosario, Argentina, 2School of Medicine. Rosario National University., Bone Biology Laboratory, Rosario, Argentina, 3School of Medicine. Rosario National University, Bone Biology Laboratory, Rosario, Argentina, 4Centro de Diagnostico Rossi, Buenos Aires, Argentina, 5Hospital Provincial, Rosario, Argentina, 6Sanatorio Británico, Rosario, Argentina, 7Centro de Endrocrinología., Rosario, Argentina

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: 25-hydroxyvitamin D, Disease Activity and rheumatologic disease

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Previous evidence indicates an association between vitamin D deficiency and autoimmune diseases. The aim of this study was to evaluate serum 25-hydroxyvitamin D (25OHD), acute phase reactants and disease activity in patients with rheumatologic diseases (RD).

Methods: This retrospective study evaluated 173 patients with RD (94 rheumatoid arthritis (RA), 18 spondyloarthropathies (SA), 61 collagenopathies (COL) (systemic lupus erythematosus, vasculitis, scleroderma, undifferentiated disease, superposition syndrome) and compared them with a control group (CG, n=121) matched by age (CG= 55.0±14.7 years; RD= 53.4±13.6, sex and body mass index (BMI). All patients were from Rosario (32º52´18´´S) and Buenos Aires (34º36´14´´S) cities. Exclusion criteria: supplementation with vitamin D, pregnancy, intestinal malabsorption, chronic liver or kidney disease, and cancer. Date are expressed as mean±SEM. Differences between groups were analyzed using the Mann-Whitney or Kruskal-Wallis tests. Correlations were performed with Spearman’s correlation test. Univariate linear regression and logistic regression analysis were performed. Contingency tables were evaluated with χ2 test. The difference was considered significant if p<0.05.

Results: RD patients had significant lower 25OHD levels as a control group (CG= 26.8±1.1 ng/ml; RD= 19.8±0.6 ng/ml; p<0.0001). Furthermore, all subgroups had lower 25OHD (RA=20.7±0.7 ng/ml, SA= 15.4±1.3 ng/ml, COL= 19.7±1.1 ng/ml). The OR of patients with RD being vitamin D deficient (25OHD <20 ng/ml) was 2.7 (95%CI 1.6 to 4.4) with a probability of 73%. Consistent with 25OHD differences, significant lower serum calcium (CG= 9.33±0.04; RD= 9.14±0.08 mg/dl) and higher PTH (CG= 39.72±2.37; RD= 49.93±3.34 pg/ml) levels were found. No differences in serum phosphate, urinary calcium and urinary deoxipiridinoline were observed. 25OHD significantly correlated with erythrocyte sedimentation rate (ERS) [r= -0.28; p=0.0017] as acute phase reactants. No differences was found in reactive C-protein (RCP). Lower values of 25OHD were found at higher DAS-28 (<3.2= 22.9 ng/ml; 3.2-5.1= 19.8 ng/ml; >5.1= 19.9 ng/ml; p=0.23) and HAQ-DI (0-1= 22.9 ng/ml; 2= 19.8 ng/ml; 3= 19.9 ng/ml; p=0.001). Activity scores in other RD couldn´t be analyzed because of the small number of patients. Age, BMI, presence of RD, RCP and HAQ-DI were significantly and inversely associated with 25OHD levels. BMI, presence of RD, ERS and RCP were significantly associated with vitamin D deficiency.

Conclusion: Patients with RD have a high probability of being deficient in 25OHD. Low 25OHD levels are associated with high acute phase reactants in the whole group, and with high disease activity scores in RA patients.


Disclosure: M. L. Brance, None; L. R. Brun, None; M. Larroude, None; M. P. Sacnun, None; C. Aeschlimann, None; G. Berbotto, None; M. Palatnik, None; I. Chavero, None; A. Sánchez, None.

To cite this abstract in AMA style:

Brance ML, Brun LR, Larroude M, Sacnun MP, Aeschlimann C, Berbotto G, Palatnik M, Chavero I, Sánchez A. Serum 25-Hydroxyvitamin D, Acute Phase Reactants and Disease Activity in Rheumatologic Diseases [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/serum-25-hydroxyvitamin-d-acute-phase-reactants-and-disease-activity-in-rheumatologic-diseases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-25-hydroxyvitamin-d-acute-phase-reactants-and-disease-activity-in-rheumatologic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology